Equibles does not estimate personal net worth.
Get an email with a short summary when Maravai Lifesciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get MRVI alertsRajesh Asarpota is recorded as CFO at Maravai Lifesciences Holdings, Inc. (MRVI). Maravai Lifesciences Holdings, Inc. reported in an 8-K filed June 25, 2025 that Rajesh Asarpota was appointed Chief Financial Officer, effective June 30, 2025. Rajesh Asarpota has spoken on 2 earnings calls across 1 company, most recently for Maravai Lifesciences Holdings, Inc. on November 4, 2026. Maravai Lifesciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Maravai Lifesciences Holdings, Inc. includes Bernd Brust (CEO and Board Member), William "Trey" Martin, III (CEO and Board Member), William E. Martin III (CEO) and 7 others.
“On June 22, 2025, the Board of Directors of Maravai LifeSciences Holdings, Inc. (the "Company") appointed Rajesh Asarpota as Chief Financial Officer of the Company, effective June 30, 2025 (the "Effective Date").”
“Our third quarter reflects continued execution across both segments. I'll focus on the key drivers behind the quarter, including revenue composition, profitability, and our updated outlook.”
“Let's turn to the Q3 financial results on Slide 12. Revenue for the quarter was $41.6 million compared to $69 million in Q3 2024. Excluding revenue for COVID GMP CleanCap, base revenue in Q3 2024 was $50.8 million.”
Biotechnology · Healthcare
CFO
